For myself the important facts are:
1. Dr Voit (who is the world leading researcher in DMD) has already confirmed the data for 1102 on a Ph 2 study. He commented “ For all other drugs on the market, patients decline. Unusual for a drug that patients improve as they did with ALT 1102”. So all we need is validation on a large Ph2b group.
2. Charmaine and Andrew have left CSL ( SP is the hundreds of dollars) after 11 and 23 year respectively to join a speculative Bio with a 40M market cap. They would not risk their reputation unless it is was a sure thing..
3. Platinum is on board with a significant holding and someone just invested 4M during the recent capital raise.
So we are now fully funded to the first data review of the Ph 2b and we have an impressive team on board with Charmaine, Andrew and also Gil Price who has links to Sarepta, FDA and PPMD community..
I think I will be taking up a few more shares with the SPP..
For myself the important facts are:1. Dr Voit (who is the world...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.002(2.04%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $50.98K | 508.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 69109 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 249627 | 5 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |